Things were quite different back in the day.
Almost a century ago, the accidental discovery of a mold on a lab dish transformed medicine forever.
What began as a chance observation in a London microbiology lab mushroomed into the antibiotic revolution, delivering one of the greatest leaps in human survival ever recorded.
Look, penicillin didn’t just cure infections, it reset the expected human lifespan and saved countless lives on the battlefields of World War II by treating infections.
That one accidental discovery opened the door to hundreds of life-saving therapies that followed its trail.
Truth is, this is how things went pretty much throughout most of human history, with medical breakthroughs depending on an unpredictable mix of intuition and error… with a little luck.
Scientists scoured the world from rainforests to ocean floors for compounds that might give them an advantage against disease.
Some discoveries took decades, and many of those leads ended up going nowhere. And yet, there were those rare miracle moments that changed everything, often arriving by pure, maddening chance.
Today, we’re finally breaking that paradigm.
I know a lot of people are screaming the word bubble when it comes to AI. And to be fair, there’s some good arguments going back and forth. However, one undeniable aspect of the AI boom taking place right now is the transition taking place in biotech.
AI is rapidly shifting from being an adjacent tool in the lab to a central driver of drug discovery and early-stage development.
Rather than hunting for needles in endless haystacks of chemical space, AI models are now running full steam to optimize drug candidates before the first vial is mixed or the first sample tested.
Breaking the Last Medical Bottleneck
Globally, AI technology being used for drug discovery has grown into a nearly $5 billion market this year and is projected to surge tenfold by 2034 as it becomes the standard for identifying targets, modeling toxicity, optimizing compounds, and designing pre-clinical pathways.
For Big Pharma, AI isn’t a mere curiosity, it’s a $50 billion treasure trove.
Of course, you don’t need to be Warren Buffett to know that the companies able to successfully deploy it early and bring their new drugs to market faster (at a lower cost, too) will reap the most rewards.
Remember, we’re talking about advantages that simply can’t be overstated in an industry where the average therapy takes 10–15 years and costs more than $2 billion to develop.
If the discovery of penicillin was the jump-off point for the beginning of modern medicine, then AI represents the next stage.
The Best Free Investment You’ll Ever Make
Our analysts have traveled the world over, dedicated to finding the best and most profitable investments in the global energy markets. All you have to do to join our Energy and Capital investment community is sign up for the daily newsletter below.
Why?
Well, because now we don’t have to rely on luck for a breakthrough; we’re building the engines that will do it on command — and the companies embracing those engines first will define the future of therapeutics.
The First Winner In the AI Drug Race
Every era of medicine is defined by its firsts.
The first antibiotic, or the first vaccine, or more recently the first gene-edited therapy.
The next milestone will be the first drug conceived, designed, optimized, and validated end-to-end by artificial intelligence.
No, I’m not talking about simply being assisted or reviewed and approved by AI.
I'm talking about being created through AI.
Now let's take this to the next level…
You see, the companies leading this transformation aren’t the legacy pharmaceutical giants that still struggle under the weight of their own infrastructure.
It’ll be those hidden investment gems constructing tomorrow’s AI-native platforms that are closest to bringing an AI-born therapy into a Phase III trial and, ultimately, to approval. They’ll be the ones building their platforms on multimodal biological datasets, reinforced learning models, and machine-generated target discovery.
Make no mistake, dear reader, when that first AI-developed drug is approved and brought to market — and we’re far closer to that than you might think, thanks to this tiny biotech player — you’re going to see the biotech game change forever.
Imagine being early to the first penicillin, before the production, before the demand, before the world understood what had been unlocked.
And you can bet the first AI-born drug won’t emerge from a legacy pharma boardroom.
Until next time,
Keith Kohl
Check us out on YouTube!A true insider in the technology and energy markets, Keith’s research has helped everyday investors capitalize from the rapid adoption of new technology trends and energy transitions. Keith connects with hundreds of thousands of readers as the Managing Editor of Energy & Capital, as well as the investment director of Angel Publishing’s Energy Investor and Technology and Opportunity.
For nearly two decades, Keith has been providing in-depth coverage of the hottest investment trends before they go mainstream — from the shale oil and gas boom in the United States to the red-hot EV revolution currently underway. Keith and his readers have banked hundreds of winning trades on the 5G rollout and on key advancements in robotics and AI technology.
Keith’s keen trading acumen and investment research also extend all the way into the complex biotech sector, where he and his readers take advantage of the newest and most groundbreaking medical therapies being developed by nearly 1,000 biotech companies. His network includes hundreds of experts, from M.D.s and Ph.D.s to lab scientists grinding out the latest medical technology and treatments. You can join his vast investment community and target the most profitable biotech stocks in Keith’s Topline Trader advisory newsletter.
